Wall Street brokerages forecast that Core Laboratories (NYSE:CLB) will report $171.06 million in sales for the current fiscal quarter, according to Zacks Investment Research. Two analysts have issued estimates for Core Laboratories’ earnings, with the lowest sales estimate coming in at $170.71 million and the highest estimate coming in at $171.40 million. Core Laboratories posted sales of $157.81 million in the same quarter last year, which suggests a positive year over year growth rate of 8.4%. The company is expected to issue its next quarterly earnings results after the market closes on Wednesday, April 25th.
According to Zacks, analysts expect that Core Laboratories will report full-year sales of $732.68 million for the current fiscal year, with estimates ranging from $724.99 million to $740.36 million. For the next fiscal year, analysts forecast that the firm will report sales of $784.37 million per share, with estimates ranging from $771.11 million to $797.62 million. Zacks Investment Research’s sales averages are an average based on a survey of research firms that cover Core Laboratories.
Core Laboratories (NYSE:CLB) last announced its quarterly earnings results on Wednesday, January 31st. The oil and gas company reported $0.58 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.58. The business had revenue of $172.00 million for the quarter, compared to the consensus estimate of $171.92 million. Core Laboratories had a return on equity of 58.25% and a net margin of 12.60%. The business’s revenue was up 15.1% on a year-over-year basis. During the same quarter last year, the business posted $0.41 EPS.
Shares of NYSE CLB traded up $1.31 during mid-day trading on Friday, hitting $118.06. The company had a trading volume of 187,463 shares, compared to its average volume of 443,313. The company has a market cap of $5,156.18, a price-to-earnings ratio of 58.73 and a beta of 1.40. Core Laboratories has a 12 month low of $86.55 and a 12 month high of $121.39. The company has a current ratio of 1.98, a quick ratio of 1.66 and a debt-to-equity ratio of 1.53.
Several hedge funds and other institutional investors have recently modified their holdings of the stock. Robeco Institutional Asset Management B.V. boosted its position in shares of Core Laboratories by 60.7% in the fourth quarter. Robeco Institutional Asset Management B.V. now owns 1,096 shares of the oil and gas company’s stock worth $120,000 after buying an additional 414 shares during the period. The Manufacturers Life Insurance Company boosted its position in shares of Core Laboratories by 63.7% in the second quarter. The Manufacturers Life Insurance Company now owns 1,128 shares of the oil and gas company’s stock worth $114,000 after buying an additional 439 shares during the period. Captrust Financial Advisors acquired a new stake in shares of Core Laboratories in the fourth quarter worth $139,000. Teachers Advisors LLC boosted its position in shares of Core Laboratories by 56.6% in the fourth quarter. Teachers Advisors LLC now owns 1,779 shares of the oil and gas company’s stock worth $195,000 after buying an additional 643 shares during the period. Finally, Callahan Advisors LLC acquired a new stake in shares of Core Laboratories in the fourth quarter worth $201,000.
Core Laboratories Company Profile
Core Laboratories N.V. provides reservoir description, and production enhancement services and products to the oil and gas industry in the United States, Canada, and internationally. It operates in two segments, Reservoir Description and Production Enhancement segments. The Reservoir Description segment comprises the characterization of petroleum reservoir rock, fluid, and gas samples to enhance production and improve recovery of oil and gas from its clients' reservoirs.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Core Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Core Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.